Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-04-14 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several board meeting agenda items, including the 2021 profit distribution plan, the 2021 fundraising funds storage and usage self-inspection report, and the proposal to reappoint the auditing firm for 2022. It references an audit report but does not contain the audit report itself or detailed financial statements. The document is a formal opinion related to board matters and audit firm appointment, not a full audit report or annual report. It is a board/management information type document announcing board meeting opinions and proposals to be submitted to the shareholders' meeting.
2022-04-14 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '年度报告摘要 2021' which translates to 'Annual Report Summary 2021'. It contains detailed financial data for the year 2021, including assets, liabilities, net profit, earnings per share, and other financial metrics. It also includes comprehensive company information such as business overview, product details, R&D projects, shareholder structure, and management assurances about the report's accuracy. The presence of an audit opinion from a CPA firm (standard unqualified opinion) further supports this as a formal annual report. The document length is 9042 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-14 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company through stock issuance. It includes specifics on fundraising amounts, usage, balances, regulatory compliance, and audit opinions. The text references regulatory guidelines on fundraising management and includes auditor and sponsor verification reports. The document is titled as a "专项报告" (special report) on fundraising funds' storage and usage, which aligns with a capital/financing update rather than a full annual or interim financial report. It is not an announcement of a report publication but the report itself, containing substantive financial data on fundraising and capital usage. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-04-14 Chinese
2021年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2021 by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the attendance of independent directors at board and shareholder meetings, their independent opinions on various company matters, and their efforts to protect investor rights. The content focuses on the duties and activities of independent directors rather than financial results or audit opinions. It is not a full annual report, audit report, or financial statement. It is a formal report by independent directors about their oversight and governance activities, which fits best under Board/Management Information (MANG) as it relates to board members' roles and responsibilities. The document length is 2554 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2022-04-14 Chinese
中审华会计师事务所（特殊普通合伙）关于北京三元基因药业股份有限公司2021年度募集资金存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Assurance Report) related to the "2021年度募集资金存放与实际使用情况" (2021 Annual Fundraising Capital Deposit and Actual Usage). It is issued by an accounting firm (中审华会计师事务所) and includes detailed information about the company's fundraising activities, the use of raised funds, and compliance with regulatory requirements. The document contains audit-like verification and assurance statements about the use of funds raised through stock issuance, including specific amounts, bank accounts, and usage details. It is not a full annual report or earnings release but a specialized audit/assurance report on fundraising capital usage. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/assurance report on a specific financial aspect (fundraising capital usage) and not the full annual report or other types of filings. The document length is substantial and contains detailed financial data and auditor conclusions, confirming it is the report itself, not just an announcement or certification letter.
2022-04-14 Chinese
第三届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the second meeting of the third Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting, attendance, and the approval of several reports including the 2021 Supervisory Board Work Report, the 2021 Annual Report and its summary, the 2021 Financial Final Accounts Report, the 2021 Profit Distribution Plan, the 2022 Financial Budget Report, and a special report on the use of raised funds. The document is an announcement of meeting resolutions and approvals, not the full annual report itself. It also states that these matters will be submitted to the shareholders' meeting for further approval. The document length is short (1989 characters), and it primarily serves as a formal meeting resolution announcement rather than a full financial report or detailed audit report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure rather than a full Annual Report (10-K) or Audit Report (AR).
2022-04-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.